Ten years with colistin: A retrospective case series

International Journal of Clinical Practice

Volumn 70, Issue 9, 2016, Pages 706-711

  Katz, David E ^a   Marchaim, D ^b   Assous, M V ^c   Yinnon, A ^c   Wiener Well, Y ^c   Ben Chetrit, E ^c  

^a HEBREW UNIVERSITY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM DERIVATIVE; COLISTIMETHATE; CREATININE; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; COLISTIN; COLISTINMETHANESULFONIC ACID;

ACINETOBACTER BAUMANNII; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CASE STUDY; CITROBACTER; COHORT ANALYSIS; DIALYSIS; DRUG USE; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE INFECTION; HEALTH CARE FACILITY; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; KIDNEY FUNCTION; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; MORGANELLA; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEUS; PROVIDENCIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SERRATIA; SINGLE DRUG DOSE; TREND STUDY; URINALYSIS; VERY ELDERLY; WARD; ANALOGS AND DERIVATIVES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALIZATION; MICROBIAL SENSITIVITY TEST; RESPIRATORY TRACT INFECTIONS; STATISTICS AND NUMERICAL DATA; URINARY TRACT INFECTIONS;

AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS;

EID: 84992712492     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12830     Document Type: Article

References (29)

1. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 2012; 10: 917–34.
2. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40: 1333–41.
3. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of Colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11–25.
4. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisted. Clin Microbiol Rev 2006; 21: 449–65.
5. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009; 22: 535–43.
6. Giamarellou H, Poulakolu G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009; 69: 1979–1901.
7. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from Colistin (polymyxin E). Expert Rev Anti Infect Ther 2007; 5: 811–21.
8. Falagas ME, Rafailidis PI, Loannidou E et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial bacterial infections: a retrospective cohort study of 258. patients. Int J Antimicrob Agents 2010; 35: 194–9.
9. Pintado V, San Miguel LG, Grill F et al. Intravenous Colistin sulphomethate sodium for therapy of infectiuons due to multidrug-resistant Gramnegative bacteria. J Infect 2008; 56: 185–90.
10. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous Colistin (Colistin methanesulphonate) for severe multidrugresistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35: 297–300.
11. Yinnon AM, Schlesinger Y, Raveh D. Recommendations for Use of Antimicrobial Agents in Common Clinical Conditions, 5th edn. Pocket book. Jerusalem (Hebrew): Hadar Publishers, 2010.
12. WHO collaborating centre for drug statistics methodology. http://www.whocc.no/atc_ddd_index/?code=J01XB01 (accessed January 2014).
13. Pogue JM, Cohen DA, Marchaim D. Polymxinresistant Acinetobacter baumannii: urgent action needed. Clin Infect Dis 2015; 60: 1304–6.
14. Paterson DL, Harris PNA. The new Acinetobacter equation: hypervirulence plus antibiotic resistance equals big trouble. Clin Infect Dis 2015; 61: 155–6.
15. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs, no ESKAPE! An update from the Infectious Disease Society of America. Clin Infect Dis 2009; 48: 1–12.
16. Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ. Four years’ experience of intravenous colomycin in an adult cystic fibrosis unit. Eur Respir J 1998; 12: 592–4.
17. Karnik ND, Sridharan K, Jadhav SP et al. Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection. Eur J Clin Pharmacol 2013; 69: 1429–36.
18. Petrosillo N, Giannella M, Antonelli M et al. Clinical experience of colisitin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother 2014; 58: 851–8.
19. Sabuda DM, Laupland K, Pitout J et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 2008; 19: 413–8.
20. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284–94.
21. Durante-Mangoni E, Signoriello G, Andini R et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 2013; 57: 349–58.
22. Batirel A, Balkan II, Karabay O et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014; 33: 1311–22.
23. Package insert for colistin sulfomethate sodium. Rafa laboratories Ltd., Jerusalem.
24. Tamma PD, Han JH, Harris AD et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum b-lactamase bacteremia. Clin Infect Dis 2015; 60: 1319–25.
25. Dalfino L, Puntillo F, Mosca A et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study Clin Infect Dis 2012; 54: 1720–6.
26. Pogue JM, Lee J, Marchaim D et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53: 897–84.
27. Kallel H, Bahloul M, Hergafi L et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28: 366–9.
28. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005; 11: 155–21.
29. Markou N, Apostolakos H, Koumoudiou C et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003; 7: R78–83.